Cancer drug target

BioReference Laboratories and its specialty oncology division GenPath, announce the launch of its next-generation sequencing (NGS) assay OnkoSight Advanced that enables deoxyribonucleic acid (DNA) mutational profiling of tumor samples. OnkoSight Advanced NGS testing provides targeted gene content that is aligned with the latest National Comprehensive Cancer Network (NCCN) and World Health Organization (WHO) guideline recommendations, to provide insights into many of the most common cancer types. Additionally, OnkoSight Advanced panels each include key biomarkers: Tumor Mutation Burden (TMB) and Tumor-Only Microsatellite (MSI), which are critical when profiling advanced stage tumor malignancies to guide potential immunotherapy. Entire exonic coding regions and selected introns are broadly covered among genes targeted for analysis. Coverage of whole exonic coding regions minimizes the risk of potential false negatives due to lack of coverage across clinically relevant genomic loci.

BioReference Laboratories

Also of Interest